Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 58, Issue 107-108, 2011, Pages 949-954

  Abdel Rehem, Rania Naguib Abdel Mouteleb ^a   El Shikh, Wafaa Mohamed Hussein Mekky ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADULT; AGED; ALKALINE PHOSPHATASE; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 80051603110     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Colakoǧlu O, Tagkiran B, Colakoǧlu G, Kizildaǧ S, Ari Ozcan F, Unsal B: Serum insulin like growth factor-1 (IGF-I) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. The Turkish Journal of Gastroenterology 2007; 18(4):245-249. (Pubitemid 351676978)
2. García-Fernández M, Castilla-Cortázar I, Díaz-Sánchez M, Díez Caballero F, Castilla A, Díaz Casares A, Varela-Nieto I, González-Barón S: Effect of IGF-I on total serum antioxidant status in cirrhotic rats. J Physiol Biochem 2003; 59:145-6.
3. Muguerza B, Castilla-Cortázar I, García M, Quiroga J, Santidrián S, Prieto J: Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta 2001; 1536:185-95. (Pubitemid 32530817)
4. Mirpuri E, García-Trevijano ER, Castilla-Cortazar I, Berasain C, Quiroga J, Rodriguez-Ortigosa C, Mato JM, Prieto J, Avila MA: Altered liver gene expression in CCl4-cirrhotic rats is partially normalized by insulin-like growth factor-I. Int J Biochem Cell Biol 2002; 34:242-252. (Pubitemid 34159139)
5. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N, Carella C: Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer 2002; 95: 2539-2545. (Pubitemid 35424040)
6. Cusi K, DeFronzo R: Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. Journal of Clinical Endocrinology and Metabolism 2000; 85:3077-3084.
7. Frystyk J, Skjaerbaek C, Dinesen B, Orskov H: Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Letters 1994; 348:185-191. (Pubitemid 24227448)
8. Tannapfel A, Wittekind C: Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis. Virchows Arch 2002; 440:345-352. (Pubitemid 34328064)
9. Fan ZR, Yang DH, Cui J, Qin HR, Huang CC: Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis. World J Gastroenterology 2001; 7:285-288. (Pubitemid 32377486)
10. Le Roith D: Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997; 336:633-640.
11. LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003; 195:127-137.
12. Scharf JG, Braulke T: The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 2003; 35:685-693.
13. Lin SB, Hsieh SH, Hsu HL, Lai MY, Kan LS, Au LC: Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J Biochem 1997; 122:717-722.
14. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K, Hintz R: Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994; 269:13779-13784. (Pubitemid 24191120)
15. Tsai JF, Jeng JE, Chuang LY, You HL, Ho MS, Lai CS, Wang LY, Hsieh MY, Chen SC, Chuang WL, Lin ZY, Yu ML, Dai CY: Serum insulin-like growth factor-II and alpha-fetoprotein as tumor markers of hepatocellular carcinoma. Tumour Biol 2003; 24:291-298. (Pubitemid 38327991)
16. Yao DF, Dong ZZ, Nantong MY: Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2007.
17. Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY: Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. ISSN 1007-9327 CN 14-1219/R World J Gastroenterology 2005; 11(30):4655-4660. (Pubitemid 41179518)
18. Aizawa Y, Shibamoto Y, Takagi I: Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 2000; 89:53-59. (Pubitemid 30451273)
19. Seef LB: Natural history of hepatitis C. Am J Med 1999; 107:10S-15S.
20. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J: EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma conclusion of the Barcellona-2000 EASL Conference. J Hepatol 2001; 35:421-430.
21. Wu YL, Ye J, Zhang S, Zhong J, Xi RP: Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 2004; 10(18):2740-3. (Pubitemid 39214514)
22. Wang XZ, Chen ZX, Zhang LJ, Chen YX, Li D, Chen FL, Huang YH: Expression of insulin-like growth factor 1 and insulin- like growth factor 1 receptor and its intervention by interleukin-10 in experimental hepatic fibrosis. World J Gastroenterology 2003; 9:1287-1291. (Pubitemid 36805670)
23. Mailer S, Juul A, Becker U, Henriksen JH: The acidlabile subunit of the ternary insulin-like growth factor complex in cirrhosis: relation to liver dysfunction. J Hepatol 2000; 32:441-446. (Pubitemid 30136859)
24. Nedic O, Nikolic JA, Prisic S, Acimovic J, Hajdukovic-Dragojlovic L: Reactivity of IGF binding protein-3 isoforms towards concanavalin A in healthy adults and subjects with cirrhosis. Addict Biol 2003; 8:81-88. (Pubitemid 36433984)
25. Donaghy AJ, Delhanty PJ, Ho KK, Williams R, Baxter RC: Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol 2002; 36(6):751-8. (Pubitemid 35177403)
26. Sidlová K, Pechová M, Kotaska K, Průsa R: Insulin-Like Growth Factor Binding Protein-3 in Patients with Liver Cirrhosis. Physiol. Res 2002; 51:587-590.
27. Conn HO: A Peek at the Child -Turcotte classification. Hepatology 1981; 1(6):673-6.
28. Tavil AS: The synthesis and degradation of liver produced proteins. Gut 1972; 13:225-235.
29. Sherlock S: Assessment of liver function. In: Sherlock S, Dooley J, eds. Diseases of the liver and biliarly system. London: Blackwell Scientific 1993; p. 17.
30. Underwood LE, Smith EP, Glommons DR: The production and actions of IGFs, their relationship to nutrition and growth. In: Tanner JM, ed. Oxford: Smith Gordon 1988; p 235-249.
31. Hintz RL: Plasma forms of somatomedin and the binding protein phenomenon. Clin Endocrinol Metab 1981; 13:31-42.
32. Ottesen LH, Bendtsen F, Flyvbjerg A: The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. Liver 2001; 21(5):350-6. (Pubitemid 32910560)
33. Lez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG: Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab 2004; 89(9):4325-30. (Pubitemid 39244433)
34. Fernández-Rodriguez CM, Prada I, Andrade A, Moreiras M, Guitián R, Aller R, Lledó JL, Cacho G, Quiroga J, Prieto J: Disturbed synthesis of insulin-like growth factor I and its binding proteins may influence renal function changes in liver cirrhosis. Dig Dis Sci 2001; 46:1313-1320. (Pubitemid 32523280)
35. Sedlaczek N, Hasilik A, Neuhaus P, Schuppan D, Herbst H: Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br Jcancer 2003; 88:733-739. (Pubitemid 36411453)
36. Inaba T, Saito H, Inoue T, Han I, Furukawa S, Matsuda T, Ikeda S, Muto T: Growth hormone/insulin-like growth factor 1 axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy J Hepatol 1999; 31:271-276. (Pubitemid 29349753)
37. Donaghy A, Ross R, Gimson A, Hughes SC, Holly J, Williams R: Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 1995; 21(3):680-8.
38. Assy N, Hochberg Z, Amit T, Shen-Orr Z, Enat R, Baruch Y: Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF-binding protein-3 in liver cirrhosis. J Hepatol 1997; 27:796-802. (Pubitemid 27454821)
39. Mattera D, Capuano G, Colao A, Pivonello R, Manguso F, Puzziello A, D'Agostino L: Increased IGF-I: IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol 2003; (59):699-706. (Pubitemid 37491573)
40. Ito S, Yao DF, Nii C, Horie T, Kamamura M, Nishikado T, Honda H, Shibata H, Shimizu I, Meng XY: Incidence of hepatitis C virus (HCV) antibodies and HCV-RNA in blood donors and patients with liver diseases in the inshore area of the Yangtze River. J Gastroenterol Hepatol 1994; 9:245-249. (Pubitemid 24149286)
41. Yao DF, Jiang DR, Huang ZW, Lu J, Tao Q, Yu Z, Meng X: Abnormal expression of hepatoma specific g-glutamyl transferase and alteration of g-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88:761-769. (Pubitemid 30091094)
42. Yao DF, Dong ZZ, Yang DM: Peripheral blood AFP mRNA amplification in the diagnosis and differential diagnosis of hepatocellular carcinoma. Zhonghua Putong Waike Zazhi 2000; 15:474-477.
43. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y: Glypican-3 over expressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16-25.
44. Shi X, Zhou Y, Xia L: Clinical evaluation of several tumor markers in the diagnosis of primary hepatic cancer. Zhonghua Zhong Liu Za Zhi 1998; 20:437-439. [In Chinese]
45. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB: Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36:S84-S92. (Pubitemid 35253467)
46. Hayakawa T, Kondo T, Shibata T, Kitagawa M, Ono H, Sakai Y, Kato K, Katada N, Sugimoto Y, Takeichi M: Serum insulin-like growth factor II in chronic liver disease. Dig Dis Sci. 1989; 34:338-342. (Pubitemid 19088771)
47. Wang Z, Ruan YB, Guan Y, Liu SH: Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol 2003; 9-2:267-270. (Pubitemid 36215801)